Akamai Technologies ends the week with shorts dug in and options traders still cautious — the defensive lean flagged Monday has not reversed.
Short interest has edged higher since the prior note. At 13.5% of free float as of June 9, it has climbed roughly 13% over the past month, with most of that build occurring between mid-May and late May as positions were rebuilt from around 16 million shares to nearly 19.5 million. The week-on-week move is modest — up less than 2% — but the direction is consistent and accumulative rather than opportunistic. Yet the borrow market continues to undercut any squeeze narrative. Availability runs at 323%, meaning there are more than three shares available to lend for every share currently borrowed. Cost to borrow at 0.46% is near a one-month low, down roughly 12% from April levels. That combination — rising short interest, loose borrow — points to a crowded but comfortable short rather than a stressed one.
The options picture shifted sharply on Tuesday. The put/call ratio closed at 0.595, nearly 2.8 standard deviations above its 20-day average of 0.37, placing it close to the 52-week high of 0.71. For most of the prior three weeks the PCR held below 0.30, so this is a genuine re-engagement with downside protection rather than residual positioning. The next earnings print is August 4, which is too far out to explain pre-event hedging — the demand for puts looks reactive to price action, with the stock down 14% on the week to $137.81 and off 6.7% over the past month.
The Street told a very different story just weeks ago. Following the May 7 earnings print — which triggered a 21% one-day gain and a 28% five-day move — analysts moved en masse to raise targets. Morgan Stanley's Keith Weiss lifted his target from $120 to $165 while holding Overweight. BofA's Madeline Brooks upgraded from Neutral to Buy with a $175 target. Across ten firms, targets moved from a range of roughly $100–$133 to $150–$195, bringing the consensus mean to $157.89 — implying around 14.6% upside from current levels. The bull case centres on Akamai's $1.8 billion frontier AI compute deal and growing cybersecurity revenues. Bears point to expected CDN revenue declines in 2026 and the capital expenditure drag from the AI partnership compressing operating margins. The analyst recommendation differentiation factor score ranks in the 98th percentile — an unusually wide spread of views that reflects genuine disagreement, not consensus drift.
Institutional ownership adds one wrinkle worth noting. BNY Asset Management added nearly 496,000 shares in the most recent filing period, and Dimensional Fund Advisors added 694,000. Both are incremental but directionally positive against a backdrop of price weakness. The ORTEX short score at 59.4 has been range-bound between 58.7 and 60.4 over the past ten sessions, suggesting no material acceleration in bearish signal intensity despite the stock's continued slide.
The key question heading into next week is whether the options defensiveness fades as the stock stabilises or deepens if the $137 level gives way — with the August 4 earnings date now eight weeks out, any PCR re-rating will need a new catalyst to sustain it.
See the live data behind this article on ORTEX.
Open AKAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
